• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Dacomitinib (PF-00299804)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS3600413

Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively. More details

$235 / 2 mg +1 FREE 8GB USB
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Dacomitinib, Biochemical
Full Product Name
Dacomitinib
Product Synonym Names
PF-00299804; PF-299804; PF 299804; PF 00299804
Purity/Purification
>98% (HPLC)
Preparation and Storage
Store at -20 degree C
Stability: >=2 years
Shipping: Ice Pack
Molecular Weight
469.9
Suitability
DMSO: >=50mg/mL (Need ultrasonic)
Target
EGFR
Receptor
EGFR; HER2/ErbB2
Chemical Name
2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)
SMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
Molecular Formula
C24H25ClFN5O2
CAS Number
1110813-31-4

Product References and Citations for Dacomitinib biochemical

1. Engelman JA, et al. Cancer Res. 2007 Dec 15; 67 (24):11924-32.
2. Gonzales AJ, et al. Mol Cancer Ther. 2008 Jul; 7 (7):1880-9.
3. Nguyen KS, et al. Clin Lung Cancer. 2009 Jul; 10 (4):281-9.
4. Kalous O, et al. Mol Cancer Ther. 2012 Sep; 11 (9):1978-87.

Other Notes

Small volumes of Dacomitinib biochemical vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Dacomitinib purchase

MBS3600413 is a biochemical targeting Dacomitinib.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000